The study identified four different types of pain among nursing home residents.

Published Date: 02 Mar 2023

Although it is recognized that pain is common among nursing home residents, little attention has been paid to how this pain changes over time. A new study from the Regenstrief Institute and the Indiana University School of Nursing...

Read Full News

Todays Updates


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD


Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD


Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists


What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio


A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli


A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH


Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Todays Updates


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA


IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD


Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD


Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists


What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio


A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli


A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH


Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

November 2023, Medical Bulletin 04/.

2.

Remote CBT for Insomnia Improves Symptoms During Chemo

3.

Vaccine shows promise for pancreatic cancer, study finds

4.

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training

5.

Some low-grade prostate cancers carry higher risks than biopsy suggests


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot